Subcategories:

Sort by:

select Language:



Eradication of yaws: a guide for programme managers

World Health Organization WHO, (2018)


This document provides guidance for countries on how to implement activities to achieve the interruption of yaws transmission. It is intended for use by national yaws eradication programmes, partners involved in the implementation of yaws eradication activities and WHO technical staff who provide technical support to countries in the eradication of yaws.
http://apps.who.int/iris/bitstream/handle/10665/25...


Guidelines for the Management of Snake-bites. 2nd edition

Word Health Organization/ Regional Office of South-East Asia, Eds.: Word Health Organization/ Regional Office of South-East Asia, (2016)


Snakebites are well-known medical emergencies in many parts of the world, especially in rural areas. Agricultural workers and children are the most affected. The incidence of snakebite mortality is particularly high in South-East Asia. Rational use of snake anti-venom can substantially reduce mortality and morbidity due to snakebites. These guidelines are a revised and updated version of Regional Guidelines for the Management of snakebites published by the WHO Regional Office in South-East Asia in 2011. These guidelines aim to promote the rational management of snakebite cases in various health facilities where trained health functionaries and quality snake antivenom are available.
http://apps.who.int/medicinedocs/documents/s17111e...


Comparative efficacy of low-dose versus standard-dose azithromycin for patients with yaws: a randomised non-inferiority trial in Ghana and Papua New Guinea

Marks, M.; O. Mitja; C. Bottomley, et al., (2018)


n this study, low-dose azithromycin did not meet the prespecified non-inferiority margin compared with standard-dose azithromycin in achieving clinical and serological cure in PCR-confirmed active yaws. Only a single participant (with presumed latent yaws) had definitive serological failure. This work suggests that 20 mg/kg of azithromycin is probably effective against yaws, but further data are needed.
https://www.thelancet.com/pdfs/journals/langlo/PII...


Prise en charge clinique des cas de fièvre hémorragique virale

World Health Organization, Regional Office for Africa;, (2016)


Guide de poche pour l’agent de santé en première ligne Ce guide s’intéresse plus particulièrement à certaines fièvres hémorragiques virales (FHV) Ebola, Marburg, FHCC, fièvre de Lassa [et Lujo] – qui surviennent en Afrique et risquent de donner lieu à une transmission interhumaine. Il ne traite pas de la prise en charge d’autres infections virales, comme la dengue, la fièvre de la vallée du Rift et la fièvre jaune, qui entraînent également des manifestations hémorragiques, mais pour lesquelles il n’y a pas de transmission directe d’une personne à une autre
http://apps.who.int/iris/bitstream/handle/10665/27...


Weekly Epidemiological Record (WER), 25 May 2018, vol. 93, no. 21 (pp.305–320) [EN/FR]

World Health Organization, (2018)


Contents 305 Dracunculiasis eradication: global surveillance summary, 2017
https://reliefweb.int/sites/reliefweb.int/files/re...


International Textbook of Leprosy

D.M. Scollard and T.P. Gillis, Eds.: American Leprosy Missions, (2018)


The International Textbook of Leprosy is dedicated to the physicians and health workers caring for their first patient with leprosy, and to all of those in the research community who have encountered some of the fascinating scientific aspects of leprosy and wish to learn more. Read online at: http://www.internationaltextbookofleprosy.org/
http://www.internationaltextbookofleprosy.org/


Fièvre de Lassa : Introduction. Cours

World Health Organization WHO, (2018)


La fièvre de Lassa est une fièvre hémorragique virale aiguë d'une durée d'une à quatre semaines qui sévit en Afrique occidentale. La fièvre de Lassa, une fièvre hémorragique virale avec des symptômes similaires à ceux de la maladie virale d'Ebola, est endémique dans une grande partie de l'Afrique de l'Ouest et provoque généralement une poussée saisonnière de Platform: OpenWHO
https://openwho.org/courses/fievre-de-lassa-introd...


A guide for surveillance of antimicrobial resistance in leprosy: 2017 update

E. A. Cooreman, Eds.: WHO SEARO/Department of Control of Neglected Tropical Diseases, (2017)


In case of resistance to rifampicin, fluoroquinolones become the preferred category of second-line drugs. Unfortunately, quinolone-resistant strains of Mycobacterium leprae have also been reported in several countries, probably due to the extensive use of quinolones for treating several types of infections. Clofazimine resistance is still rare but this antimicrobial cannot be given alone
http://apps.who.int/iris/bitstream/10665/259357/3/...


182 hits